Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Laiyi Chua"'
Autor:
Ivelina Gueorguieva, Brian A. Willis, Laiyi Chua, Kay Chow, C. Steven Ernest II, Jian Wang, Sergey Shcherbinin, John R. Sims, Emmanuel Chigutsa
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 9, Iss 2, Pp n/a-n/a (2023)
Abstract INTRODUCTION Donanemab is an amyloid‐targeting therapy that specifically targets brain amyloid plaques. The objective of these analyses was to characterize the relationship of donanemab exposure with plasma biomarkers and clinical efficacy
Externí odkaz:
https://doaj.org/article/46f199eccdf94cd1a9b67b5c825effb4
Autor:
Stephen Loucian Lowe, Brian A. Willis, Anne Hawdon, Fanni Natanegara, Laiyi Chua, Joanne Foster, Sergey Shcherbinin, Paul Ardayfio, John R. Sims
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021)
Abstract Introduction This study explored the safety and tolerability features of donanemab (LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild to moderate AD dementia. Methods Patients with AD were enrolled
Externí odkaz:
https://doaj.org/article/fc3a8ec9b31144a59529adb9909dc026
Autor:
Ivelina Gueorguieva, Brian A. Willis, Laiyi Chua, Kay Chow, C. Steven Ernest, Sergey Shcherbinin, Paul Ardayfio, Garrett R. Mullins, John R. Sims
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:1258-1267
Publikováno v:
Alzheimer'sdementia : the journal of the Alzheimer's AssociationREFERENCES.
An Alzheimer's disease (AD) dementia disease progression model was developed based on the integrated Alzheimer's Disease Rating Scale (iADRS).Data from 3483 placebo participants in six AD trials were used to develop the disease progression model with
Autor:
Paul A. Ardayfio, Sergey Shcherbinin, Y.-J. Cheng, Laiyi Chua, Albert Lo, G. Takaichi, John R. Sims, I. Gueorguieva, Stephen L. Lowe, Jeffrey L. Dage, C. Duggan Evans, G. Mullins, G. Aguiar, Adam S. Fleisher, M. Ishibai, Brian A. Willis
Publikováno v:
Journal of Prevention of Alzheimer's Disease. :1-11
Background: Donanemab (LY3002813) is an IgG1 antibody directed at an N‑terminal pyroglutamate of amyloid beta epitope that is present only in brain amyloid plaques. Objectives: To assess effects of donanemab on brain amyloid plaque load after singl
Autor:
Amy S. Paller, Kimberley Jackson, Marieke M B Seyger, Claudia Rodriguez Capriles, Perla Lansang, Kim A. Papp, Nieves Velez de Mendizabal, Laiyi Chua, Celine Pitou
Publikováno v:
British Journal of Clinical Pharmacology, 88, 1074-1086
British Journal of Clinical Pharmacology, 88, 3, pp. 1074-1086
British Journal of Clinical Pharmacology, 88, 3, pp. 1074-1086
Contains fulltext : 248294.pdf (Publisher’s version ) (Open Access) AIMS: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17A used in the treatment of adult and paediatric patients with moderate-to-severe psor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e731f2bb601ccea9fce16a6c24a136e
http://hdl.handle.net/2066/248294
http://hdl.handle.net/2066/248294
Autor:
Laiyi Chua, Feng Wang, Yongjia Ji, Yerong Yu, Lai San Tham, Tianyang Ma, Helle Linnebjerg, Hui Liu, Hongying Li
Publikováno v:
Clinical pharmacology in drug developmentReferences. 10(12)
Insulin glargine (IGlar) and LY2963016 (LY IGlar) are long-acting insulin analogs with identical primary amino acid sequences. We conducted a randomized, open-label, 2-treatment, 2-period, crossover study in healthy Chinese subjects to evaluate the r
Autor:
Paul A. Ardayfio, Brian A. Willis, John R. Sims, Stephen L. Lowe, Laiyi Chua, Joanne Foster, Anne Hawdon, Sergey Shcherbinin, Fanni Natanegara
Publikováno v:
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021)
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021)
Introduction This study explored the safety and tolerability features of donanemab (LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild to moderate AD dementia. Methods Patients with AD were enrolled into the
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 6:804-813
Baricitinib is an oral inhibitor of Janus kinases (JAKs), selective for JAK1 and 2. It demonstrated dose-dependent efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) in a phase IIb study up to 24 weeks. Population pharmacokinetic/
Autor:
Xin Zhang, Laiyi Chua, Christoph Kapitza, David E. Coutant, Mary E. Seger, Helle Linnebjerg, Tim Heise, Eric Chen Quin Lam
Publikováno v:
Diabetes, Obesity and Metabolism. 19:33-39
Aims LY2963016 (LY IGlar) and Lantus (IGlar) are insulin glargine products manufactured by distinct processes, but with identical amino acid sequences. This study compared the duration of action of LY IGlar and IGlar in subjects with type 1 diabetes